TrialCancer cell2023
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).
Yunpeng Yang et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
138 papers cite itlatest 60 shown
this paperpooled ittrialcites it